Optimising Trial Design to Achieve Personalised prevention of Alzheimer’s disease

Alzheimer’s disease (AD) is among the largest health care challenges of our century. Curative treatments are not yet available. The most likely explanation for this lack of treatment is that treatment should be personalized and early (i.e. focus on prevention). OTAPA aims to fundamentally improve the design of prevention trials by identifying subgroups of patients with AD, replicating this in the earlier (preclinical) disease stage and then establish recommendations to improve trial design. OTAPA makes use of existing data sets: Brain Research Center has access to clinical trial data sets, and the Alzheimer Center Amsterdam runs the observational SCIENCe cohort. If successful, OTAPA contributes to a future of personalised prevention of AD. By designing more efficient and effective trials, OTAPA contributes to finding treatments for AD at the right time, for the right patient. 

For more information click here.